This new license is an addition to an existing license agreement under which ETS uses Scorpions to detect organisms which could cause spoilage in wine or juice. While DxS’ real-time PCR Scorpions technology can be utilised in a wide range of genetic diagnostic applications, it can be used for a variety of other purposes including environmental analysis, food testing and biothreat detection, due to its high sensitivity and fast reaction times.
Dr Stephen Little, CEO of DxS said: “This new agreement shows just how effective Scorpions is, not just as an in vitro diagnostic, but also for other uses where testing needs to be done quickly and with a high degree of sensitivity. We are very pleased to be able to be able to provide this additional license, which allows ETS to maintain its position as the world leader in the detection of contaminating organisms.”
Gordon Burns, President of ETS Laboratories added: “Scorpions has proven itself to be an excellent technology allowing ETS to quickly and efficiently test wines for potentially damaging contaminants and we know it will be equally effective for monitoring biofuel fermentations.”
Financial terms were not disclosed.
DxS is a personalised medicine company providing products, technology and services to the healthcare industry to enable the delivery of safe and effective medicines. The Company has also established itself as a leader in the provision of companion diagnostics to the personalised cancer medicine market.
DxS has a range of products including cancer mutation assays and kits, molecular diagnostic technologies and genetic analysis services. Its TheraScreen® range of CE-marked kits can identify genetic tumour mutations affecting how patients respond to cancer therapies, enabling doctors and drug companies to provide the treatment most likely to benefit patients. DxS produce two clinical diagnostic kits, K-RAS, and EGFR-29. The K-RAS assay has been chosen as the companion diagnostic for Amgen’s colorectal cancer therapy Vectibix®. DxS has an exclusive global distribution agreement with Roche Molecular Systems for the distribution of the TheraScreen K-RAS Mutation Test and TheraScreen EGFR 29 Mutation Test.
DxS’ real-time PCR technology, Scorpions® utilises its speed and sensitivity and underpins the products and services. This class-leading technology is also available for licence to diagnostic companies, for research, applied and other applications.
DxS is a private, venture capital backed company operating from Manchester’s Technology Quarter within the UK.
For further information please visit www.dxsdiagnostics.com
